Compare Torrent Pharma with Lupin - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs LUPIN - Comparison Results

TORRENT PHARMA     Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

LUPIN 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA LUPIN TORRENT PHARMA/
LUPIN
 
P/E (TTM) x 35.1 40.5 86.7% View Chart
P/BV x 8.9 3.7 238.8% View Chart
Dividend Yield % 0.7 0.6 117.7%  

Financials

 TORRENT PHARMA   LUPIN
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-19
LUPIN
Mar-20
TORRENT PHARMA/
LUPIN
5-Yr Chart
Click to enlarge
High Rs1,964882 222.6%   
Low Rs1,245505 246.5%   
Sales per share (Unadj.) Rs453.4339.4 133.6%  
Earnings per share (Unadj.) Rs25.8-5.9 -433.6%  
Cash flow per share (Unadj.) Rs62.315.5 402.6%  
Dividends per share (Unadj.) Rs17.006.00 283.3%  
Dividend yield (eoy) %1.10.9 122.5%  
Book value per share (Unadj.) Rs279.2276.7 100.9%  
Shares outstanding (eoy) m169.22453.00 37.4%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.52.0 173.2%   
Avg P/E ratio x62.2-116.6 -53.4%  
P/CF ratio (eoy) x25.844.8 57.5%  
Price / Book Value ratio x5.72.5 229.3%  
Dividend payout %65.9-100.9 -65.3%   
Avg Mkt Cap Rs m271,513314,201 86.4%   
No. of employees `00013.618.3 74.3%   
Total wages/salary Rs m14,03829,868 47.0%   
Avg. sales/employee Rs Th5,642.68,400.6 67.2%   
Avg. wages/employee Rs Th1,032.41,632.0 63.3%   
Avg. net profit/employee Rs Th320.9-147.2 -218.0%   
INCOME DATA
Net Sales Rs m76,728153,748 49.9%  
Other income Rs m5714,838 11.8%   
Total revenues Rs m77,299158,585 48.7%   
Gross profit Rs m19,83124,849 79.8%  
Depreciation Rs m6,1779,702 63.7%   
Interest Rs m5,0383,630 138.8%   
Profit before tax Rs m9,18716,355 56.2%   
Minority Interest Rs m04 0.0%   
Prior Period Items Rs m039 0.0%   
Extraordinary Inc (Exp) Rs m-3,570-7,521 47.5%   
Tax Rs m1,25411,571 10.8%   
Profit after tax Rs m4,363-2,694 -162.0%  
Gross profit margin %25.816.2 159.9%  
Effective tax rate %13.670.8 19.3%   
Net profit margin %5.7-1.8 -324.5%  
BALANCE SHEET DATA
Current assets Rs m50,375154,132 32.7%   
Current liabilities Rs m51,65392,252 56.0%   
Net working cap to sales %-1.740.2 -4.1%  
Current ratio x1.01.7 58.4%  
Inventory Days Days9282 112.2%  
Debtors Days Days68129 52.8%  
Net fixed assets Rs m83,64889,082 93.9%   
Share capital Rs m846906 93.4%   
"Free" reserves Rs m46,397124,461 37.3%   
Net worth Rs m47,244125,367 37.7%   
Long term debt Rs m39,12917,933 218.2%   
Total assets Rs m141,209249,839 56.5%  
Interest coverage x2.85.5 51.3%   
Debt to equity ratio x0.80.1 579.0%  
Sales to assets ratio x0.50.6 88.3%   
Return on assets %6.70.4 1,777.1%  
Return on equity %9.2-2.1 -429.8%  
Return on capital %12.38.7 141.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m22,10351,450 43.0%   
Fx outflow Rs m5,52219,470 28.4%   
Net fx Rs m16,58131,980 51.8%   
CASH FLOW
From Operations Rs m17,98114,688 122.4%  
From Investments Rs m-2,41311,070 -21.8%  
From Financial Activity Rs m-13,145-8,906 147.6%  
Net Cashflow Rs m2,38016,853 14.1%  

Share Holding

Indian Promoters % 71.5 46.6 153.4%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 7.0 11.3 62.1%  
FIIs % 12.6 31.9 39.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 10.1 87.1%  
Shareholders   26,511 98,259 27.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   UNICHEM LAB  VENUS REMEDIES  CIPLA  GLENMARK PHARMA  AUROBINDO PHARMA  

Compare TORRENT PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Wipro's Biggest Acquisition, Vodafone Idea Fundraising Plan, and Buzzing Stocks Today(Pre-Open)

Indian share markets witnessed huge selling during closing hours on Friday and ended lower.

Related Views on News

LUPIN 2019-20 Annual Report Analysis (Annual Result Update)

Dec 7, 2020 | Updated on Dec 7, 2020

Here's an analysis of the annual report of LUPIN for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

LUPIN Announces Quarterly Results (2QFY21); Net Profit Up 271.3% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, LUPIN has posted a net profit of Rs 2 bn (up 271.3% YoY). Sales on the other hand came in at Rs 38 bn (down 12.0% YoY). Read on for a complete analysis of LUPIN's quarterly results.

TORRENT PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 27.0% (Quarterly Result Update)

Oct 27, 2020 | Updated on Oct 27, 2020

For the quarter ended September 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 27.0% YoY). Sales on the other hand came in at Rs 20 bn (up 0.6% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

LUPIN Announces Quarterly Results (1QFY21); Net Profit Down 64.2% (Quarterly Result Update)

Aug 18, 2020 | Updated on Aug 18, 2020

For the quarter ended June 2020, LUPIN has posted a net profit of Rs 1 bn (down 64.2% YoY). Sales on the other hand came in at Rs 35 bn (down 20.2% YoY). Read on for a complete analysis of LUPIN's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 48.6% (Quarterly Result Update)

Jul 31, 2020 | Updated on Jul 31, 2020

For the quarter ended June 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 48.6% YoY). Sales on the other hand came in at Rs 21 bn (up 1.7% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Make Rs 5,000 Per Day Trading the Market(Fast Profits Daily)

Feb 25, 2021

In this video, I'll show you how to get started on the path to daily trading profits.

The Hidden Tesla in My Great Indian Wealth Project(Profit Hunter)

Feb 23, 2021

An Indian company founded three decades ago in a garage caught my attention...

Gold 65,000 and Silver 84,000 in 2022

Feb 26, 2021

In this episode of the Investor Hour, India's #1 trader, Vijay Bhambwani, talks to us about the stock market, his new targets for gold and silver, the best long-term investment opportunity, and a lot more.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Mar 5, 2021 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 8-QTR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS